Skip to content

Neural and Cognitive Consequences of COVID-19 Survival

Neural and Cognitive Consequences of COVID-19 Survival

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06208943
Enrollment
150
Registered
2024-01-17
Start date
2021-10-01
Completion date
2025-09-30
Last updated
2024-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Fog, Concentration Ability Impaired, COVID-19, COVID-19 Pandemic, COVID Long-Haul, Fatigue, Memory Deficits

Keywords

EEG, fMRI, MRI, functional MRI, brain fog, long COVID, fatigue, difficulty concentrating, memory difficulty

Brief summary

The novel coronavirus SARS-CoV-2 infection, COVID, continues to rage throughout the world with 115,000,000 confirmed cases and over 2,500,000 deaths (as of Mar 3, 2021). This translates to millions of people surviving COVID19 infection. While the lungs are ground zero, COVID tears through organ systems from brain to blood vessels. We are now beginning to see people recover but complain of ongoing problems, including lingering cognitive problems, depression, and anxiety. We have brought together 2 laboratories with complementary techniques including psychological testing and neuroimaging methods togethers with markers in the blood that may signal damage in the brain. A close look at these problems is timely and imperative if we are to understand the pathophysiology of 'COVID brain' and prepare for downstream problems.

Detailed description

The SARS-CoV-2 pandemic has been going on for over a year worldwide, with 115,000,000 confirmed cases and over 2,500,000 deaths (as of Mar 3, 2021). We are seeing people recover from the initial COVID infection with complaints of ongoing problems. An increasing number of people are complaining of cognitive deficits and depression/anxiety. Methodologically, we have brought together two laboratories studying neurocognitive impairment using an EEG, MRI, and behavioral approach as well as laboratory-based data. This study queries neuropsychological functions in individuals using a neuropsychological battery, EEG-based measures, functional MRI (connectivity) and structural MRI (gray and white matter volumes, myelin, micro-bleeds). In addition, we have preliminary data to show a continued increase in plasma cytokines in COVID survivors. Plasma isolated neuronal enriched extracellular vesicles (nEVs) showed an increase in amyloid beta, neurofilament light and pT181-Tau, all proteins associated with neurodegeneration. The overall aim is to determine the extent of cognitive, clinical, and neurological damage in people recovered from COVID.

Interventions

n/a there is no intervention in this observational study

Sponsors

San Francisco Veterans Affairs Medical Center
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco. * Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner. * 18-70 years with a confirmed COVID infection at least 3 months ago. * Negative metal screen for MRI safety * Normal (or corrected to normal) vision

Exclusion criteria

* Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms) * Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms * Major medical conditions (e.g., seizures disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology) * Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions * Known claustrophobia * Current pregnancy * IQ estimate \< 70

Design outcomes

Primary

MeasureTime frameDescription
Change of Neuropsychological Test Performance1 monthWe will compare NP test performance in people with Covid-related worsening of attention, memory, anxiety, and/or depression to people who do not endorse worsening in those domains.
Number of Participants with EEG Latency & Amplitude1 monthWe will compare EEG-derived event related potential measures of neural speed in people with Covid-related worsening of attention, memory, anxiety, and/or depression to people who do not endorse worsening in those domains.
Number of Participants with MRI Functional Disconnectivity1 monthWe will compare thalamo-cortical connectivity in people with Covid-related worsening of attention, memory, anxiety, and/or depression to people who do not endorse worsening in those domains.
Number of Participants with Blood Biomarkers1 monthWe will correlate blood biomarkers of inflammation and NP test performance, thalamo-cortical connectivity, and measures of neural speed.

Countries

United States

Contacts

Primary ContactKaitlyn L Dal Bon, BA
kaitlyn.dalbon@ucsf.edu(415) 629-9514
Backup ContactKen Lau, BS
ken.lau@ucsf.edu(415) 562-4334

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026